Aptinyx (APTX) Reports Q2 Loss of $0.27/sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. SPY
10. FISV

Go back to Aptinyx (APTX) Reports Q2 Loss of $0.27/sh

Aptinyx Reports Second Quarter 2020 Financial Results and Highlights

August 13, 2020 4:05 PM EDT

Completed enrollment in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in 4Q 2020

Recommencement of Phase 2 studies of NYX-2925 in chronic pain expected soon

Conference call today at 5:00 p.m. ET

EVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2020 and highlighted recent progress across the companys clinical-stage pipeline of novel NMDA receptor... More